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ABSTRACT 
Purpose: Development of RNA interference based therapeutics for neurological and 
neurodegenerative diseases is hindered by a lack of non-viral vectors with suitable properties 
for systemic administration. Amphiphilic and cationic cyclodextrins (CD) offer potential for 
neuronal siRNA delivery. Here, we aimed to improve our CD-based siRNA formulation 
through incorporation of a polyethyleneglycol (PEG) shielding layer and a cell penetrating 
peptide, octaarginine (R8). 
Methods: CD.siRNA complexes were modified by addition of an R8-PEG-lipid conjugate. 
Physical properties including size, charge and stability were assessed. Flow cytometry was 
used to determine uptake levels in a neuronal cell model. Knockdown of an exogenous gene 
and an endogenous housekeeping gene were used to assess gene silencing abilities. 
Results: CD.siRNA complexes modified with R8-PEG-lipid exhibited a lower surface charge 
and greater stability to a salt-containing environment. Neuronal uptake was increased and 
significant reductions in the levels of two target genes were achieved with the new 
formulation. However, the PEG layer was not sufficient to protect against serum-induced 
aggregation.   
Conclusions: The R8-PEG-lipid-CD.siRNA formulation displayed enhanced salt-stability 
due to the PEG component, while the R8 component facilitated transfection of neuronal cells 
and efficient gene silencing. Further improvements will be investigated in the future in order 
to optimise stability in serum and enhance neuronal specificity. 
Keywords: siRNA, neuronal delivery, cyclodextrins, octa-arginine 
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ABBREVIATIONS 
CD: cyclodextrin 
CNS: central nervous system 
DLS: dynamic light scattering 
DMSO: dimethylsulphoxide 
DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
DIW: deionised water 
GAPDH: glyceraldehyde phosphate dehydrogenase 
MR: mass ratio 
mRNA: messenger RNA 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
PAMAM: polyamidoamine 
PEG: polyethyleneglycol 
PLL: poly-L-lysine 
ns: non-silencing 
R8: octaarginine 
RLU: relative luminescence units 
siRNA: small interfering RNA 
shRNA: short hairpin RNA 
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INTRODUCTION 
The potential for RNA interference-based therapeutics for diseases of the central nervous 
system (CNS) has received much attention (1-3). Delivery of small interfering RNAs 
(siRNA) to neurons and the CNS remains an obstacle and, to date, cationic lipids are the most 
extensively used non-viral vectors (4). Cyclodextrins (CDs) have shown great promise as 
gene delivery vectors in various cell types (5-13). Furthermore, in pre-clinical studies, CD-
based vectors have shown favourable toxicity profiles, with no effect on body weight and 
liver enzymes (8, 14, 15). We have recently developed an amphiphilic cationic β-CD for 
neuronal siRNA delivery, which exhibited minimal toxicity in neuronal cell lines and primary 
hippocampal neurons, whilst achieving up to 40% reduction in expression of the target 
housekeeping gene (16). However, progress towards systemic administration requires 
substantial developments in this formulation. Of particular focus are modifications which will 
confer stability in a salt and serum environment, thereby reducing interaction with plasma 
components, whilst maintaining high levels of cellular permeation and gene silencing with 
improved specificity and targeting. 
The ‘ABCD’ approach to designing nanoparticles for nucleic acid delivery can be applied 
when considering appropriate components of a formulation (17). ‘A’ denotes the nucleic acid 
cargo, in this case siRNA, which is complexed or encapsulated by ‘B’, the amphiphilic 
cationic CD. Here we use a CD which has been shown to mediate high intracellular siRNA 
levels and knockdown in neurons (16), but tends to aggregate on exposure to salt- or serum- 
containing medium and therefore is expected to have poor stability and short circulation time 
in vivo. Therefore, an additional component ‘C’, which represents a polyethyleneglycol 
(PEG) shielding layer, should be considered to enhance the stability of the formulation by 
minimising interaction with negatively charged plasma proteins and erythrocytes (18-20). 
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However, shielding of the surface of cationic siRNA-containing nanoparticles with a PEG 
layer can impair cellular uptake and reduce or even eliminate their gene silencing abilities 
(21-23). To overcome this, a targeting or cell penetrating ligand ‘D’ can be included as the 
final component in the formulation (19).  
Octaarginine (R8) is a model peptide ligand, which can be attached via the PEG moieties to 
assist in cell penetration. R8 has been used itself or in combination with vectors to transfer 
genes and siRNA into a variety of cell types in vitro (18, 24, 25) and in vivo (26, 27). In terms 
of neuronal delivery, stearylated R8 achieved moderate levels of gene knockdown (~50%) in 
primary hippocampal neurons (28) and a polyarginine vector, modified with myristic acid, 
reduced target mRNA expression by 25% in primary cortical neurons (29). Furthermore, both 
shRNA (short-hairpin RNA) and siRNA were successfully delivered to primary cortical 
cultures using a cationic polyamidoamine (PAMAM) dendrimer to which R8 was grafted (30, 
31). 
We have previously described a co-formulation approach whereby two CDs, one neutral and 
the other cationic were mixed together before siRNA complexation, to achieve nanoparticles 
with improved stability but which lacked gene silencing efficiency in non-neuronal (21) and 
neuronal cells (unpublished data), which was attributable, at least in part, to a reduction in 
cellular uptake. Efforts to synthesise a PEGylated CD with a neuronal specific targeting 
ligand attached are ongoing, but have proved complex. Therefore, we investigated an 
alternative approach to varying the CD.siRNA formulation. 
One strategy for the modification of nanoparticles at their surface is by ‘post-insertion’ (32). 
This method describes the transfer to nanoparticles of amphiphilic molecules which exist in 
micellar form and has been extensively reported for liposomes (33, 34) and lipid 
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nanocapsules (35). Post-insertion has also been recently used for the surface modification of 
siRNA containing cationic liposomes with PEG and transferrin (36). 
An ‘insertion’ type approach was, therefore, investigated for the modification of pre-formed 
CD.siRNA complexes. R8, in the form of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
(DSPE)–PEG2000-R8, was inserted into the surface of CD.siRNA complexes, yielding a novel 
modified R8-PEG-DSPE-CD.siRNA formulation, which was assessed in terms of its physical 
properties and its silencing efficacy. It was hypothesised that the PEG component would 
stabilise the complexes and the R8 would aid in transfer across neuronal cell membranes. 
 
MATERIALS AND METHODS 
siRNAs 
Negative control siRNA (sense sequence 5’- UUC UCC GAA CGU GUC ACG U), 
fluorescein labelled siRNA (sense sequence 5’- UUC UCC GAA CGU GUC ACG U, 
modified with 3’-fluorescein on the sense strand), pGL3 luciferase siRNA (sense sequence 
5’- CUU ACG CUG AGU ACU UCG A) and GAPDH siRNA (sense 5’- GGU CGG UGU 
GAA CGG AUU U) were obtained from Qiagen (California, USA). 
Preparation of CD.siRNA complexes 
An amphiphilic cationic CD, SC12CDclickpropylamine, was synthesized as reported (21). 
CD.siRNA complexes were prepared as described (16, 21). Briefly, the required amount of 
CD was dissolved in chloroform (1 mg/ml). The solvent was removed under a gentle stream 
of nitrogen. Aliquots were stored at -20 ºC until required. CDs were rehydrated with 
deionised water (DIW) (final concentration 1 mg/ml) and sonicated for 1 hour at room 
temperature, then mixed with siRNA in an equal volume of DIW and incubated for 15-20 
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minutes at room temperature. A cationic CD:siRNA mass ratio (MR, µg CD: µg siRNA) of 
20 was chosen (16). 
For in vivo experiments, 5% glucose was used in place of DIW. 
Synthesis of DSPE-PEG2000-R8 
DSPE-PEG2000-R8 was synthesized as follows. AcCysβAla(Arg)8H was synthesized on a 0.1 
mmol scale on an automated peptide synthesizer (Applied Biosystems, Model 433A; 
Framingham, MA, USA) using Fmoc solid-phase peptide synthesis.  The 
fluorenylmethoxycarbonyl amino acids Fmoc-Arg(Pbf)-OH, Fmoc-βAla-OH and Fmoc-
Cys(Trt)-OH (Merck Millipore, Germany) were coupled using 10 equivalents of O-
Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) and 
Hydroxybenzotriazole (HOBt) and the Fmoc groups were deprotected using DIEA.  The 
peptide was cleaved from the resin and the side chains were deprotected in 
TFA/TIS/H2O/EDT (92.5/2.5/2.5/2.5) for 4.5 h.  The product was purified by HPLC on a C18 
column (Phenomenex, Cheshire, UK) to yield 55 mg of peptide.   
AcCysβAla(Arg)8H (55mg, 0.023mmol, as TFA salt) was dissolved in 10 mL of phosphate 
buffer at pH 7.  10 mmol Mal-Peg(2000)-DSPE (61 mg, 0.0207 mmol; Avanti Polar Lipids 
Inc., AL, USA) was diluted with  19 mL of acetonitrile. Both solutions were degassed under 
nitrogen prior mixing together and the biphasic mixture was stirred overnight.  The solvents 
were evaporated and the mixture purified by HPLC on C5 column (Phenomenex, Cheshire, 
UK) using a column heater at 60°C to obtain the product as the TFA salt (18.5 mg, 
0,00347mmol, 15% yield).  The product purity was determined to be 70% by analytical 
HPLC.   
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HRMS-MALDI-TOF (m/z): [M + H]
+
 calcd. for C191H375N36O67PS, 4311.26096; found, 
4366.3800. 
Preparation of R8-PEG-CD.siRNA formulation 
For preparation of micelles, DSPE-PEG-R8 was hydrated with MES buffer (20 mM HEPES, 
20 mM MES, pH 6.5), above the critical micelle concentration (2.3 µM) (33). This was 
followed by vortex mixing, heating to 38 °C for ten minutes and a second vortex mixing (36). 
The size range of the resulting particles was 20-30 nm.  
Finally, 5 to 20 mol % (DSPE-PEG2000-R8-trifluoroacetate relative to 
SC12CDClickpropylamine) of R8-PEG-DSPE was added to the CD.siRNA complexes and 
left overnight (~ 18 hours) at 38 °C (36). The CD.siRNA MR was maintained at 20, 
irrespective of the amount of DSPE-PEG-R8 added to the formulation.  
For pharmacokinetic studies, complexes were concentrated by ultrafiltration (37, 38). 
Vivaspin centrifugal concentrators (Vivascience) with a molecular weight cut off of 3000 
were used. Complexes were added to the concentrator tubes and centrifuged at 2000 xg at 4 
°C until concentrated to the required volume. 
Gel Retardation Assay 
siRNA complexation was determined by agarose gel electrophoresis (20), after modifying the 
formulation with R8-PEG. CD.siRNA complexes (MR20), or R8-PEG-DSPE-CD.siRNA 
complexes, were mixed with loading buffer and DIW to a final volume of 20 µl (containing 
0.3 µg siRNA). Samples were added to wells in a 1% agarose gel containing SafeView™ 
(NBS Biologicals Ltd, England) (6 µl/100 mls). Electrophoresis was carried out at 90 V for 
20 minutes, with a Tris-borate-EDTA buffer (39). Bands corresponding to the DNA ladder 
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(100 b.p.) and unbound siRNA were visualised by UV, using the DNR Bioimaging Systems 
MiniBis Pro and Gel Capture US B2 software. 
Size and Charge Measurements 
Particle Z-average size and charge were measured with Malvern’s Zetasizer Nano ZS, using 
dynamic light scattering (DLS) and electrophoretic mobility measurements respectively. 
CD.siRNA and R8-PEG-DSPE-CD.siRNA complexes were prepared and made up to 1 ml 
with 0.2 µm filtered DIW. Five readings of Z-average size (nm), polydispersity (25
o
C, 
measurement angle 170
o
) and zeta potential (mV) (25
o
C, measurement angle 12.8
o
) were 
taken. For data analysis, the viscosity (0.8872 mPa.s) and refractive index (1.33) of water 
were used to determine Z-average size. These data are presented as mean ± S.D. 
Aggregation Studies 
Stability of formulations upon exposure to salt-containing medium or serum were 
investigated by incubating CD.siRNA or R8-PEG-DSPE-CD.siRNA complexes in either 
OptiMEM® transfection medium (40, 41) or foetal bovine serum (FBS) (20) at 37 ºC for 
various lengths of time. Following this, size measurements were carried out by DLS as 
before.  
Cell culture 
A mouse embryonic hypothalamic cell line (mHypoE N41) (42) was obtained from tebu-bio 
(France) and was maintained in Dulbecco’s modified Eagle’s medium (DMEM, Sigma), 
supplemented with 10 % foetal bovine serum (FBS, Sigma) in a humidified 37 
o
C incubator 
with 5 %  CO2. Cells were seeded in 12- well, 24- well and 96- well plates at 6.6 x 10
4
, 3.5 x 
10
4
 and 1.5 x 10
4
 cells per well respectively. This cell line is a useful model for neuronal cells 
(16). 
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MTT Toxicity Assay  
The MTT assay is widely used as an indicator of the toxicity caused to neurons by non-viral 
vectors (43, 44). This assay measures the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide) by mitochondrial dehydrogenase, in viable cells only, to 
give a dark blue product. However, as it only measures one end-point, namely the change in 
mitochondrial integrity, it is not a direct measure of cell viability. Cells were seeded in 96- 
well plates 1 day prior to transfection. siRNA (100 nM) alone, or in CD.siRNA or R8-PEG-
DSPE-CD.siRNA complexes, was diluted in OptiMEM®, then added to cells in serum-
containing medium for 24 hours. Media was removed and replaced with 100 µl fresh media 
and MTT (20 µl of a 5 mg/ml solution) for four hours, after which the formazon crystals 
produced were dissolved in 100 µl DMSO. Absorbance was measured at 590 nm using a UV 
plate reader. Each experiment was carried out in triplicate. Results were expressed as % 
dehydrogenase activity compared to untreated controls. These data are presented as the mean 
± SEM.  
Cellular uptake experiments 
The level of uptake mediated by transfection complexes was assessed by flow cytometry (20, 
44). Fluorescently labelled siRNA (Qiagen) was used for these experiments. Cells were 
seeded in 24 well plates 1 day prior to transfection. siRNA (50 nM) alone, or in CD.siRNA or 
R8-PEG-DSPE-CD.siRNA complexes, was diluted in OptiMEM®, then added to cells in 
serum-containing medium for 24 hours. Following this, complexes bound to the extracellular 
surfaces were removed by washing with phosphate buffered saline (Sigma) and by incubation 
with 250 µl of CellScrub buffer (Genlantis) for 15 minutes at room temperature (20, 45). 
Cells were removed from the wells and prepared for analysis following several washing 
steps. The fluorescence associated with 10,000 cells was measured with a FACS Caliber 
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instrument (BD Biosciences) and data were analysed using Cell Quest Pro software. Each 
experiment was carried out in triplicate. These data are presented as the mean ± SEM. 
Knockdown of luciferase reporter gene 
Silencing of an exogenous gene was assessed by measuring knockdown of a luciferase 
reporter plasmid as previously described (20, 21). Cells were seeded in 24 well plates 1 day 
prior to transfection. Cells were transfected with pGL3-luc (1 µg/well) complexed to 
Lipofectamine
TM
 2000 (2.5 µl/µg pDNA) for three hours.  Following this, cells were washed 
twice with phosphate buffered saline (Sigma) prior to siRNA transfection. pGL3-luciferase 
siRNA (50 nM) alone, in CD.siRNA complexes or in R8-PEG-DSPE-CD.siRNA complexes, 
was diluted in OptiMEM® and added to the cells in serum-containing medium. Complexes 
containing negative control siRNA (ns siRNA) were included as controls. NH2-PEG-DSPE-
CD.siRNA complexes were also included, which lacked in the R8 ligand. After 24 hours, 
cells were washed with PBS, lysed with 400 µl of 1x Reporter Lysis Buffer (Promega) and 
frozen at -80 ºC. Lysate was collected and centrifuged for 5 min at 13000 rpm. A sample of 
the supernatant (20 µl) was assayed for expression of luciferase by adding to 100 µl of 
luciferin (Promega) and measuring the light produced (relative luminescence units, RLU) 10 
seconds later in a Junior LB 9059 luminometer (Promega). Total protein levels in each 
sample were determined by the BCA Protein Assay (Thermo Scientific). Luciferase 
expression for each sample was calculated as RLU per microgram protein. Luciferase 
expression of the ‘Untreated’ control samples (which were transfected with luciferase 
plasmid only but no siRNA)  was taken as 100% and for all other samples, gene expression 
was calculated as a % of this untreated control.  Each experiment was carried out in triplicate. 
These data are presented as the mean ± SEM. 
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Knockdown of endogenous GAPDH 
Silencing of an endogenous gene was assessed by measuring knockdown of the housekeeping 
gene, glyceraldehyde dehydrogenase phosphate (GAPDH) (46, 47). Cells were seeded in 12 
well plates for 1 day before transfection. GAPDH-siRNA (100 nM) alone, or in CD.siRNA or 
R8-PEG-DSPE-CD.siRNA complexes, diluted in OptiMEM®, was added to the cells in 
serum-containing medium. Complexes containing negative control siRNA (ns siRNA) were 
included as controls. After 24 hours, total RNA was extracted from N41 cells using 
Stratagene Absolutely RNA® Miniprep Kit, according to the manufacturer’s instructions. 
The concentration of RNA was measured by UV absorbance on the NanoDrop ND-1000 UV-
Vis Spectrophotometer and RNA integrity was confirmed by analysis using the Agilent 2100 
Bioanalyzer. A high-capacity cDNA reverse transcriptase kit (Applied Biosystems) was used 
for complementary DNA (cDNA) synthesis. Gene expression was assessed by real-time 
qPCR using the Applied Biosystems Real Time PCR System (Model 7300). Assays were 
performed using appropriate primer sets for GAPDH and β-actin (TaqMan®, Applied 
Biosystems). β-actin endogenous gene was used for relative gene quantification (47). The 2–
delta Ct method was used to calculate relative changes in mRNA (48). Each experiment was 
carried out in triplicate. Results were expressed as % GAPDH gene expression relative to 
untreated (non-transfected) controls. These data are presented as the mean ± SEM. 
Experimental animals 
Male Balb/c mice of age 8-10 weeks (20-22 g) were purchased from Harlan Laboratories 
(UK). Animals were given at least one week to habituate in the animal facility with food and 
water ad libitum, on a 12/12 h reversed dark-light cycle with temperature 22 ± 1°C. All 
experiments carried out on animals were in accordance with institutional ethics guidelines 
and the European Community Directive (86/609/EEC). 
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Pharmacokinetic study 
Mice (n=5 per group) were injected with FAM-labelled siRNA (40 µg), either uncomplexed 
or in concentrated R8-PEG-DSPE-CD.siRNA complexes (MR20, 20% PEG R8), via the tail 
vein. At various time points, blood (20-30 µl) was sampled from the saphenous vein and 
plasma was isolated. Plasma concentrations of FAM-siRNA were determined by fluoresence 
measurements post extraction as previously described (49). Briefly, plasma (10 µl) was 
incubated for 10 minutes at 65°C with lysis buffer (90 µl; 0.1% sodium dodecyl sulphate in 
PBS). Methanol (200 µl) was added and samples were incubated for 10 minutes at 90°C, then 
centrifuged at 14000 rpm for 5 minutes. Supernatant (100 µl) was added to wells in a black 
96-well plate and the fluoresence was measured by plate reader (λex 465 nm and λem 520 nm). 
The concentration of FAM-labelled siRNA in each sample was determined from a prepared 
standard curve. 
The extraction efficiency for siRNA was ~99% and for R8-PEG-CD.siRNA was ~90% and 
sample concentrations were corrected for these extraction efficiencies. 
Statistical analysis 
One-way analysis of variance (ANOVA) was used to compare multiple groups followed by 
Bonferroni’s post hoc test. A two-tailed student’s t-test was used to compare the 
pharmacokinetic parameters from the two groups. Statistical significance was set at *p < 
0.05. 
 
RESULTS 
CD.siRNA complexes, R8-PEG-DSPE-CD.siRNA complexes (5 mol% R8-PEG-DSPE) and 
R8-PEG-DSPE-CD.siRNA complexes (20 mol% R8-PEG-DSPE) will be referred to as MR 
20, MR 20 5% R8 and MR 20 20% R8 respectively in the relevant figures. In preliminary 
experiments, there was little difference between CD.siRNA complexes modified with 5 
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mol% R8-PEG-DSPE compared to 10 mol%, therefore we eliminated the latter from further 
investigations. 
Physical properties of R8-PEG-DSPE-CD.siRNA complexes 
Firstly, we investigated whether the insertion of R8-PEG-DSPE to CD.siRNA complexes 
interfered with complexation, by gel electrophoresis (Fig. 1(a)). A band corresponding to free 
siRNA was visible in the siRNA lane only, indicating that siRNA remained fully complexed 
after insertion of 5 or 20 mol % R8-PEG-DSPE.  
Having confirmed that siRNA remained complexed after the insertion process, size and 
charge measurements were carried out.  
The particle sizes (Z-Ave) of CD.siRNA complexes before and after insertion of R8-PEG-
DSPE were measured by dynamic light scattering. CD.siRNA complexes measured 91.5 ± 4 
nm, with slight increases in sizes observed after insertion, up to 113.7 ± 4.6 nm for R8-PEG-
DSPE-CD.siRNA (20 mol % R8-PEG-DSPE) (Fig. 1 (b)). Surface charge (zeta potential) of 
complexes was also determined. All complexes were cationic, although zeta potentials 
decreased from + 53.3 mV to + 38.9 mV with the inclusion of 20 mol% R8-PEG-DSPE (Fig. 
1 (c)). The effect of insertion, therefore, was to slightly increase the particle size and to 
reduce the zeta potential. 
Effects of salt-containing medium and serum on R8-PEG-DSPE-CD.siRNA complexes 
Cationic particles are known to aggregate in salt-containing medium and on exposure to 
serum, whilst PEGylation can help to prevent these effects. Therefore, CD.siRNA complexes 
(MR 20) and R8-PEG-DSPE-CD.siRNA complexes (MR 20, 20% R8) were incubated in 
OptiMEM® or FBS for various lengths of time and the particles sizes and presence of 
aggregates was determined by dynamic light scattering. Incubation in a salt-environment 
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caused significant aggregation of CD.siRNA complexes, particularly after 12 and 72 hours 
(Fig. 2 (a)). On the other hand, there was no aggregation evident after incubation of R8-PEG-
DSPE-CD.siRNA in OptiMEM®, indicating greater stability due to the presence of a R8-
PEG-DSPE layer (Fig. 2 (a)). 
The effects of serum incubation were also examined. After 24 hours incubation in FBS, both 
CD.siRNA and R8-PEG-DSPE-CD.siRNA complexes showed some degree of aggregation, 
as illustrated by a shift to the right in the size intensity profile of the FBS treated samples 
(Fig. 2 (b, c)). A time course of the aggregation of the complexes in serum was also carried 
out (Supplementary Fig. 1). This illustrated that both CD.siRNA and R8-PEG-DSPE-
CD.siRNA complexes showed a similar extent of aggregation at each time point tested. The 
extent to which the complexes aggregated was greater for the longest incubation period (72 
hours). 
In designing vectors for siRNA delivery, it is also important to consider the stability of 
siRNA on exposure to serum nucleases (19). Indeed, in our recently published work we 
showed that SC12CDClickpropylamine confers protection to and prevents degradation of 
complexed siRNA for at least four hours, with some intact siRNA recovered after 24 hours, 
compared to naked siRNA which was degraded within minutes (16). 
Viability of neuronal cultures after treatment with R8-PEG-DSPE-CD.siRNA 
complexes 
Modification of the CD.siRNA formulation with R8-PEG-DSPE led to greater impairment of 
neuronal cell viability. CD.siRNA complexes (MR20 0% R8) caused minimal toxicity (Fig. 3 
(a)), whereas complexes modified with 20 mol% of R8-PEG-DSPE reduced cell viability to 
~74%. Toxicity was most pronounced with 50 mol % R8-PEG-DSPE (60.8 ± 2.9 %, *p < 
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0.05 relative to MR20 0% R8) and this formulation was, therefore, excluded from further in 
vitro investigations.  
Uptake of R8-PEG-DSPE-CD.siRNA complexes 
Modification of the surfaces of cationic vectors with a PEG shielding layer has been shown to 
reduce uptake of the nucleic acid cargo, likely due to impairing non-specific interactions with 
the cell membrane (50). One approach to overcoming this challenge is the linking of a ligand 
via the PEG groups, which can improve association with the cell membrane, whilst 
maintaining the stabilising effects of the PEG (51-53).  
To investigate the intracellular delivery of R8-PEG-DSPE-CD.siRNA complexes, FAM-
labelled siRNA was used in complexes and uptake measured by flow cytometry. High levels 
of uptake were achieved with the CD.siRNA formulation (MR20; 50 ± 6%). Insertion of R8-
PEG-DSPE led to even higher levels of uptake, with up to 69.3 ± 0.2% of neuronal cells 
positive for FAM-siRNA after treatment with the MR20 20% R8 formulation (Fig. 3 (b)). 
Low levels of autofluoresence were equivalent for all formulations (data not shown), 
indicating that the increase in uptake was not due to toxicity.  
Gene knockdown mediated by R8-PEG-DSPE-CD.siRNA complexes 
The transfection efficiencies of PEGylated siRNA vectors are variable, with different reports 
depending on the cell type, nature of the vector and the type of linker to the PEG groups (20, 
22, 23, 54). Therefore, we investigated the ability of R8-PEG-DSPE-CD.siRNA complexes to 
reduce expression of two target genes, luciferase reporter plasmid and GAPDH housekeeping 
gene.  
A specific and significant reduction in luciferase expression was achieved with both the 
unmodified CD.siRNA (MR20) and the R8-PEG-DSPE-CD.siRNA (MR20 20% R8) 
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formulations (Fig. 4 (a)). In fact, almost 80% knockdown was achieved with the MR20 20% 
R8 formulation (*p < 0.05 relative to untreated cells). A NH2-PEG-DSPE-CD.siRNA 
formulation was also included in these experiments and this did not have a significant effect 
on gene expression (Fig. 4(a)).In this formulation, the PEG terminated in a free amine, rather 
than the R8. This demonstrates that the PEG moiety in the formulation reduced gene 
silencing efficiency, as previously shown (21, 23). 
Knockdown experiments targeting a highly expressed endogenous gene, GAPDH, were also 
carried out. Both unmodified CD.siRNA complexes (MR20) and MR20 20% R8 mediated a 
modest but significant reduction in GAPDH expression (~ 40%, *p < 0.05 relative to 
untreated controls) (Fig. 4 (b)). 
In both of these studies, neither free siRNA nor non-silencing siRNA controls had any effects 
on the target gene expression. 
These data demonstrate that the modified R8-PEG-DSPE-CD.siRNA complexes retain the 
gene silencing capabilities of unmodified CD.siRNA complexes, despite the presence of a 
steric shielding PEG layer. 
Pharmacokinetic studies  
Pharmacokinetic studies were carried out comparing the R8-PEG-DSPE-CD.siRNA 
formulation (MR20 20% R8) with free siRNA.  
Mice were administered a tail vein injection of either FAM-labelled siRNA alone or 
complexed in a MR20 20% R8 formulation. Blood was sampled from the saphenous vein at 
various time points and the plasma was isolated. Plasma concentration of FAM-siRNA was 
determined by fluorescence. After 20 minutes, the concentration of free FAM-siRNA was 
below the detection limit (49), indicating that it had been rapidly eliminated from the blood 
18 
 
(Fig. 5). This represents a characteristic plasma concentration profile for free siRNA (49, 55). 
Differences were observed in the profile obtained with R8-PEG-DSPE-CD.siRNA (MR 20 
20% R8), with plasma levels of formulated siRNA three-fold higher than naked siRNA at ten 
minutes post administration. However, the prolonged circulation observed here is modest 
relative to that observed with other PEGylated formulations. For example, while here we 
report a significant increase in half-life for formulated siRNA compared to free siRNA (Table 
1, 15.7 ± 4.4 mins compared to 2.3 ± 0.9 mins), the half-life of siRNA in non-targeted neutral 
nanoparticles was extended to 20 hours (49). Furthermore, in a study comparing PEGylated 
poly-lysine-based (PLL) siRNA vectors, a formulation containing high molecular weight 
PEG (10,000 Da) achieved a significant prolongation of circulation time and slower clearance 
than the other formulations, whereas the PEG2000-PLL formulation was eliminated rapidly 
(56). The cationic nature of our formulation is likely to have influenced the relatively rapid 
clearance. For example, cationic liposomal and polymer vectors for siRNA and pDNA 
exhibited similar profiles to free nucleic acids after i.v. administration, due to their positive 
charge and subsequent opsonisation (57). 
Other pharmacokinetic parameters were also calculated based on a one compartment model 
and these data are shown in Table I. The volume of distribution (Vd) was significantly 
reduced in the free siRNA group. Indeed, the difference in distribution of the two 
formulations is obvious from the plasma concentration profile, whereby the plasma levels 
differ significantly after 2 minutes (Fig. 5). The clearance (Cl) was also significantly higher 
for free siRNA. The parameters reported here with our CD-based formulation relative to free 
siRNA represent a similar trend to those reported for siRNA in non-targeted and targeted 
neutral nanoparticles, although the effect of our formulation is certainly less dramatic (49).   
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Table I. Comparison of the pharmacokinetic parameters of fluorescently-labelled 
siRNA alone or in an R8-PEG-DSPE-CD.siRNA formulation (MR 20, 20% R8). 
 t1/2 
(min) 
AUC 
(min.ng/µl) 
Vd 
(ml) 
Cl 
(ml/min) 
siRNA *2.3 ± 0.9 56.1 ± 20.3 *11.87 ± 0.97 *3.97 ± 1.17 
     
R8-PEG-
DSPE-
CD.siRNA 
15.7 ± 4.4 79.9 ± 19.4 31.03 ± 6.29 1.43 ± 0.37 
Abbreviations: t1/2 (half-life), AUC (area under the curve), Vd (volume of distribution), Cl 
(clearance). The data from the plasma concentration profiles were fitted to a one 
compartment model and key pharmacokinetic parameters were calculated. *p < 0.05 
compared to R8-PEG-DSPE-CD.siRNA treated animals. 
 
DISCUSSION 
The optimisation of formulation strategies for facilitating effective siRNA-mediated gene 
knockdown in neurons is a crucial step in the development of RNAi-based CNS therapeutics 
(58). Here we have identified a novel approach for countering some of the barriers towards 
effective vector development. These data build on previous studies whereby a cationic 
amphiphilic CD, SC12CDclickpropylamine, was shown to complex siRNA, protect it from 
degradation on exposure to serum nucleases and mediate high levels of neuronal uptake and 
specific and efficient gene silencing (16). However, in accordance with its cationic nature, 
this CD has a high tendency to aggregate, particularly in a high salt and serum containing 
environment which is more representative of the in vivo situation. Moreover, the 
aforementioned delivery system lacks components for addition of targeting ligands and 
specificity, which could improve transfection and performance on systemic administration. 
Previously, we developed a co-formulation of a PEGylated and cationic CD which displayed 
some improvements in stability but was not effective at mediating RNAi (21). Therefore, as 
an alternative approach, we now report post-modification of preformed CD.siRNA 
complexes with an R8-PEG-lipid conjugate. In this way, we modified the complexes with a 
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‘C’ shielding layer (PEG2000) and a ‘D’ layer for neuronal uptake (R8) as per the ABCD 
nomenclature described by Kostarelos and Miller (17).   
A PEG molecular weight of 2000 was selected, based on previous reports that PEG molecular 
weight (MW) of at least 2000 to 5000 was required to confer good stability to nanoparticles 
(54, 59). Our previous work showed that PEG500 was not sufficient to confer serum stability 
to a PEG/cationic CD co-formulation (21). Therefore, the commercially available DSPE-
PEG2000 was chosen as a starting material for the synthesis of the R8 derivative. It is worth 
noting that even further increases in PEG MW may be required to achieve optimal stability. 
As outlined in the introduction, R8 is a cell penetrating peptide which has shown 
effectiveness in mediating gene and siRNA delivery to neurons. Liposomes containing PEG 
and R8 components have been used previously for siRNA delivery (18, 60). Finally, this 
peptide serves as a model ligand for this type of CD–based formulation and there may be 
potential for other neuron-specific peptides to be used in its place.  
 The ‘post-modification’ method described here was based on a post-insertion approach 
previously optimised for liposomes (36). Insertion of R8-PEG-DSPE to CD.siRNA altered 
the properties of the complexes, with a slight reduction in charge and a slight increase in size 
(Fig. 1), indicating that some degree of transfer had taken place. A method for quantitatively 
assaying the amount of material which has inserted into the surface of CD.siRNA complexes 
remains elusive to us, due to the difficulty in separating free R8-PEG-DSPE micelles from 
those which have been transferred. Indeed, it has been acknowledged that determining the 
yield of successfully modified nanoparticles after post-insertion poses great difficulties and 
requires further consideration (32). With regards to the current study, the alterations in 
physical properties and stability of post-inserted complexes imply that the complex surfaces 
were to some extent modified with the R8-PEG-DSPE.  
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A more pronounced reduction in zeta potential was anticipated, due to the shielding effects of 
the high MW PEG component. In fact, a previous study has shown that incorporation of 
DSPE-PEG into liposomal formulations significantly reduced the surface charge (61). 
However, our R8-PEG-DSPE-CD.siRNA complexes remained positively charged, which 
may be attributed to the cationic nature of the attached R8 (zeta potential of R8-PEG-DSPE 
alone was ~ 20mV, data not shown). In spite of their positive charge, the post-inserted 
complexes (MR20 20% R8) were resistant to aggregation in a salt-containing medium. 
However, there was an increase in complex sizes after incubation in serum. A further increase 
in PEG MW (up to 5000 Da) may be required to prevent serum-induced aggregation (54).  
Inclusion of a PEG component has often been associated with a drop in transfection 
efficiency (22, 23). Indeed, in our previous studies, inclusion of a PEGylated CD in the 
CD.siRNA formulation eliminated gene silencing capabilities (21). This was due to a 
reduction in cellular uptake. However, in the current study there was a small but significant 
increase in uptake with 20% R8 in the R8-PEG-DSPE-CD.siRNA formulation. This occurred 
despite a reduction in surface charge, indicating that the R8 component facilitated transfer 
across the cell membrane, which counter-balances the shielding effect of PEG. For this 
reason, CD.siRNA complexes with 20% R8-PEG-DSPE and unmodified CD.siRNA 
complexes achieved equivalent gene silencing. The levels of gene knockdown were similar to 
those achieved with a commercial vector, Lipofectamine
TM
 2000 (16). 
Finally, in a preliminary pharmacokinetic investigation we assessed the plasma concentration 
profiles of free siRNA compared to siRNA in the MR20 20% R8 formulation. Typically, 
following i.v. administration free siRNA is rapidly eliminated and has a short half-life, 
ranging from seconds to minutes (49, 62), as observed in our study. Although the MR20 20% 
R8 formulation altered the plasma concentration profile of siRNA and increased its half-life 
by several minutes, these were limited effects. Taken together with the tendency of the 
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formulation to aggregate on exposure to serum, these data indicate that the PEG component 
did not confer sufficient steric stability to the formulation. Neutral PEGylated vectors achieve 
a significant prolongation of siRNA circulation and ultimately represent a more desirable 
approach (49). It is worth noting that a comprehensive biodistribution analysis is also 
necessary to fully assess the utility of targeted gene delivery vectors and such studies, 
coupled with in vivo toxicity studies, will be required for further in vivo development of the 
formulation. 
The approach described herein offers itself as proof of principle for attaching other PEG-
targeting ligands to neutral CD.siRNA complexes. Indeed, such a system offers great 
prospects for application to the CNS, with many favourable properties including the small 
sized complexes and the high levels of transfection efficiency demonstrated in neurons. 
Although the R8 peptide may not be the most feasible ligand for CNS delivery, using this 
approach, either transferrin or the rabies virus glycoprotein peptide, which enhance neuronal 
siRNA delivery and transfer across the blood brain barrier, could be considered as alternative 
ligands for future development (63-65). 
 
CONCLUSIONS 
In summary, we successfully modified the CD.siRNA formulation, with the addition of R8-
PEG-DSPE by to preformed complexes, resulting in a suitable formulation for neuronal 
delivery. Properties of the new formulation were improved, including a reduction in surface 
charge and significant resistance to salt-induced aggregation. High levels of neuronal uptake 
in vitro and subsequent silencing of two target genes were achieved. Cell viability was 
maintained at greater than 70% after treatment with the new formulation. Limitations of the 
current formulation include its cationic nature, tendency to aggregate in serum and lack of 
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specificity, rendering it less useful for long-term in vivo use. Indeed, the development of a 
neutral PEGylated formulation with a targeting ligand is the ultimate goal for siRNA-based 
therapeutics.  
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Figures 
 
Figure 1. Physical properties of R8-PEG-DSPE-CD.siRNA complexes. (a) Gel retardation 
assay examining siRNA binding properties, (b) Size (Z-Ave (nm)) and (c) charge (zeta 
potential (mV)) of CD.siRNA and R8-PEG-DSPE-CD.siRNA complexes in DIW. Data are 
presented as the mean ± S.D (n = 3). 
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Figure 2. Stability of CD.siRNA (MR20) or R8-PEG-DSPE-CD.siRNA (MR20 20% R8) 
complexes after incubation in (a) OptiMEM® for 2, 12 or 72 hours or (b) and (c) 90% FBS 
for 24 hours.  
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Figure 3. (a) Toxicity in mHypoE N41 neuronal cells was determined by MTT assay after 
treatment with CD.siRNA (MR 20) or R8-PEG-DSPE-CD.siRNA (MR 20 20% R8) 
complexes (100 nM siRNA) for 24 hours. (b) Uptake of CD.siRNA (MR 20) or R8-PEG-
DSPE-CD.siRNA (MR 20 20% R8) complexes (50 nM siRNA) in mHypoE N41 neurons. 
Cells were treated for 24 hours before measuring uptake by flow cytometry. Uptake was 
expressed as percentage of fluorescent siRNA positive cells. Data are expressed as mean ± 
SEM (n = 3). *p < 0.05 relative to unmodified CD.siRNA complexes (MR 20). 
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Figure 4. (a) Knockdown of luciferase reporter gene in mHypoE N41 neurons by CD.siRNA 
(MR 20) or R8-PEG-DSPE-CD.siRNA (MR 20 20% R8) complexes (50 nM siRNA). 
Luciferase expression was calculated as a percentage of RNAi- untreated cells. NH2-PEG-
DSPE-CD.siRNA (MR 20 20% NH2) complexes were included as a control lacking in R8. (b) 
Knockdown of endogenous GAPDH in mHypoE N41 neurons by CD.siRNA or R8-PEG-
CD-DSPE.siRNA complexes (100 nM siRNA). GAPDH expression was calculated as a 
percentage of RNAi-untreated cells. Data are expressed as the mean ± SEM (n = 3). *p < 
0.05 relative to untreated controls. 
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Figure 5. Plasma concentration profiles of FAM-labelled siRNA alone, or formulated with 
R8-PEG-DSPE-CD.siRNA (MR20 20% R8). Data are presented as mean ± S.E.M (n= 3-5).  
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Supplementary Figure 1. Size intensity profiles of (a) MR 20 0% R8 and (b) MR 20 20% 
R8 after incubation in FBS for 0, 2, 24 and 72 hours.  
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